

Ari Dworsky

Chicago, Illinois | (612) 559-5880 | aridworsky@yahoo.com | www.aridworsky.com

PROFESSIONAL CHARACTERISTICS

Scope Alignment

*Allowing outcomes to define
planning and objectives*

Innovative Thinking

*Creative Solutions that are
Dynamic and Impactful*

Analytical Orientation

*Turning Complex Data into
Actionable Insights*

Operational Excellence

*Optimizing Process for
Maximum Efficiency*

CASE STUDIES

GE Healthcare — Multinational Capital Budgeting Report

Directed a capital budgeting analysis for the potential new manufacturing facility for CT scanners in Poland, providing key insights into the project's viability and long-term financial implications

- Conducted a comprehensive financial evaluation for a new CT scanner manufacturing facility, forecasting future demand, pricing, variable costs, and foreign currency exchange
- Utilized key financial models such as CAPM, NPV, and IRR to assess the viability and profitability of the investment project
- Provided risk identification analysis and proposed financial strategies to mitigate risks and optimize the project's outcome
- Informed executive decision-making on whether to proceed with the investment, contributing valuable strategic insights

BP Amoco — Financial Analysis of Key Financial Statements

Led the financial analysis of BP Amoco's performance through the COVID-19 pandemic, evaluating liquidity, profitability, and operational efficiency during a period of significant market disruption

- Performed an in-depth financial review of BP Amoco's operations during the COVID-19 pandemic, assessing its resilience and financial health through key financial ratios and performance metrics
- Conducted a terminal valuation of free cash flow to estimate the company's long-term value and its impact on equity holders
- Provided insights into BP's financial resilience and strategic positioning post-pandemic, helping inform future financial planning and executive strategies.

NGMBIO & MERCK — Drug Discovery Report: NGM621 for Geographic Atrophy

Evaluated the financial and strategic implications of NGM621, a drug aimed at treating geographic atrophy, focusing on the effects of its phase 2 trial failure for both NGM Biopharmaceuticals and Merck

- Analyzed the NGM621 drug development project, exploring its mechanism of action and competitive landscape for geographic atrophy and age-related macular degeneration
 - Evaluate the financial and portfolio consequences of the phase 2 trial failure, analyzing its effect on NGM Biopharmaceuticals' stock performance and Merck's long-term strategy for its drug candidate portfolio
 - Integrated scientific and business analysis to assess market dynamics and forecast potential shifts in corporate strategy's
 - Contribute to strategic recommendations for Merck's ophthalmology pipeline and NGM's financial position proceeding
-

RESEARCH

Neuropharmacology Graduate Research Rotation

Profiling Drug-Mediated SERT Activity with False Fluorescent Neurotransmitters

- Developed a preliminary drug screening assay investigating serotonin (5-HT) uptake and efflux transport through SERT
- Utilized False Fluorescent Neurotransmitter 246 (FFN-246) to measure 5-HT uptake, providing data of transport dynamics
- Optimized experimental protocols to enhance accuracy and precision in characterizing SERT activity using FFN-246
- Studied monoamine neurotransmission in the synaptic cleft, focusing on the mechanisms regulating 5-HT efflux via SERT
- Analyzed the impact of drug candidates on SERT activity using protein assay data to assess their pharmacological effects
- Presented research findings to the team and principal investigator, guiding direction for future experiments and research goals